DUPIXENT DISTINCTLY SHOWED IMPROVEMENT IN LUNG FUNCTION IN PATIENTS WITH CRSwNP AND COEXISTING ASTHMA5,6,i,j,*

Post hoc pooled analysis from SINUS-24 and SINUS-52
in pre-bronchodilator FEV1 at Week 24 between DUPIXENT 300 mg Q2W + INCS (n=176) and placebo + INCS (n=124) (95% CI: 110, 310 mL)5,6

*Patients with baseline blood EOS levels ≥300 cells/μL.5,6

Post hoc analysis was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be made.5,6

According to the DUPIXENT Prescribing Information, in subjects with CRSwNP and coexisting asthma, improvements in pre-bronchodilator FEV1 were similar to those of subjects in the DUPIXENT asthma program.4

DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitations of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

iPatients with coexisting asthma enrolled in the CRSwNP clinical trials had a mean FEV1 84% predicted at baseline. Patients with FEV1 ≤50% predicted were excluded. Patients were not selected based on minimum biomarker or asthma severity requirements.3,5,6

jA majority of patients in the CRSwNP trials were on oral steroids to treat CRSwNP, which may affect baseline EOS levels.3,5,7

INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.